Disclosed is a method for producing an antibody reagent for detecting a test substance in a sample by an immune complex transfer method. The method comprises the steps of: bringing an antibody solution comprising a labeled antibody capable of binding to the test substance into contact with a solid phase used in the immune complex transfer method; and separating the solid phase and the antibody solution to prepare the antibody reagent from the antibody solution.

Disclosed is a method for producing an antibody reagent for detecting a test substance in a sample by an immune complex transfer method. The method comprises the steps of: bringing an antibody solution comprising a labeled antibody capable of binding to the test substance into contact with a solid phase used in the immune complex transfer method; and separating the solid phase and the antibody solution to prepare the antibody reagent from the antibody solution.

Disclosed are compositions and methods related to the use of sialoglycan as markers for the diagnosis and prognosis of cancers and inflammatory conditions. In one aspect, also disclosed herein are engineered probes and chimeric probes with differential binding ability to sialoglycans.

Disclosed are compositions and methods related to the use of sialoglycan as markers for the diagnosis and prognosis of cancers and inflammatory conditions. In one aspect, also disclosed herein are engineered probes and chimeric probes with differential binding ability to sialoglycans.

The present invention pertains to an enzymatic measurement method using an antibody-enzyme complex or a nucleic acid probe measurement method using an enzyme-labeled nucleic acid probe, in both of which the quantification of a product of a reaction by an enzyme in the antibody-enzyme complex or the enzyme-labeled nucleic acid probe is performed by generating thio-NAD(P)H by an enzymatic cycling reaction using NAD(P)H, thio-NAD(P), and a dehydrogenase (DH), and measuring the amount of the generated thio-NAD(P)H or measuring a change in color caused by the generated thio-NAD(P)H. An enzymatic reaction system in which NAD(P) generated from NAD(P)H by the enzymatic cycling reaction is selectively reduced, is caused to coexist with the enzymatic cycling reaction. The present invention also pertains to a kit for enzyme immunoassay, and a kit for nucleic acid probe measurement. In the enzymatic cycling reaction, the detection sensitivity is increased by increasing the amount of thio-NAD(P)H generated per unit time with respect to a predetermined amount of a substrate (reduced), and combining the same with an enzyme immunoassay, etc., enables quantification, etc., of a protein or nucleic acid with high sensitivity.

The present invention pertains to an enzymatic measurement method using an antibody-enzyme complex or a nucleic acid probe measurement method using an enzyme-labeled nucleic acid probe, in both of which the quantification of a product of a reaction by an enzyme in the antibody-enzyme complex or the enzyme-labeled nucleic acid probe is performed by generating thio-NAD(P)H by an enzymatic cycling reaction using NAD(P)H, thio-NAD(P), and a dehydrogenase (DH), and measuring the amount of the generated thio-NAD(P)H or measuring a change in color caused by the generated thio-NAD(P)H. An enzymatic reaction system in which NAD(P) generated from NAD(P)H by the enzymatic cycling reaction is selectively reduced, is caused to coexist with the enzymatic cycling reaction. The present invention also pertains to a kit for enzyme immunoassay, and a kit for nucleic acid probe measurement. In the enzymatic cycling reaction, the detection sensitivity is increased by increasing the amount of thio-NAD(P)H generated per unit time with respect to a predetermined amount of a substrate (reduced), and combining the same with an enzyme immunoassay, etc., enables quantification, etc., of a protein or nucleic acid with high sensitivity.

Match-paired monoclonal antibodies against major royal jelly protein 4 (MRJP4) are secreted by hybridoma cell lines having microbial deposit numbers of CGMCC No. 17294 and CGMCC No. 17295, which are used in an ELISA kit and a colloidal gold immunoassay strip for detecting the MRJP4. The positive and MRJP4-specific cell lines are obtained by cell fusion using an antigen of MRJP4 recombinant protein and a cross-reaction with other major royal jelly proteins. The MRJP4 recombinant protein is used as an antigen to obtain several positive cell lines by cell fusion and two MRJP4-specific fusion cell lines are obtained by a cross-reaction with other major royal jelly proteins. Primary screening of a matched antibody pair is performed according to antibody pairing for recognizing different epitopes.

Match-paired monoclonal antibodies against major royal jelly protein 4 (MRJP4) are secreted by hybridoma cell lines having microbial deposit numbers of CGMCC No. 17294 and CGMCC No. 17295, which are used in an ELISA kit and a colloidal gold immunoassay strip for detecting the MRJP4. The positive and MRJP4-specific cell lines are obtained by cell fusion using an antigen of MRJP4 recombinant protein and a cross-reaction with other major royal jelly proteins. The MRJP4 recombinant protein is used as an antigen to obtain several positive cell lines by cell fusion and two MRJP4-specific fusion cell lines are obtained by a cross-reaction with other major royal jelly proteins. Primary screening of a matched antibody pair is performed according to antibody pairing for recognizing different epitopes.

Platforms for enzymatic assays for biomarkers, including systems, methods, and measuring devices by which a biomarker, such as creatinine, is measured using a small amount of biological fluid, such as blood, plasma, or serum. The measuring device or biosensor can be a test strip including a layered active component assembly positioned between two outer layers which enables multi-step enzymatic reactions operating in kinetic and/or endpoint (in which the reaction is allowed to near completion), and generally includes multiple layers with primary enzyme(s), coupling enzyme(s), and reagents to produce an optical signal correlated to the concentration of a biomarker in the sample. The test strip can be read using a portable optical reader coupled to a smart phone or tablet.

Platforms for enzymatic assays for biomarkers, including systems, methods, and measuring devices by which a biomarker, such as creatinine, is measured using a small amount of biological fluid, such as blood, plasma, or serum. The measuring device or biosensor can be a test strip including a layered active component assembly positioned between two outer layers which enables multi-step enzymatic reactions operating in kinetic and/or endpoint (in which the reaction is allowed to near completion), and generally includes multiple layers with primary enzyme(s), coupling enzyme(s), and reagents to produce an optical signal correlated to the concentration of a biomarker in the sample. The test strip can be read using a portable optical reader coupled to a smart phone or tablet.